Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2

Xu，Kun1; Gao，Ping2,3; Liu，Sheng4; Lu，Shuaiyao5; Lei，Wenwen6; Zheng，Tianyi7; Liu，Xueyuan8; Xie，Yufeng9; Zhao，Zhennan2,3; Guo，Shuxin10; Tang，Cong5; Yang，Yun5; Yu，Wenhai5; Wang，Junbin5; Zhou，Yanan5; Huang，Qing5; Liu，Chuanyu11; An，Yaling12; Zhang，Rong11; Han，Yuxuan12; Duan，Minrun13; Wang，Shaofeng2,3; Yang，Chenxi2,3; Wu，Changwei14; Liu，Xiaoya14; She，Guangbiao14; Liu，Yan15; Zhao，Xin2; Xu，Ke6; Qi，Jianxun2; Wu，Guizhen6; Peng，Xiaozhong5,16; Dai，Lianpan2,3; Wang，Peiyi4; Gao，George F.1,2,3,12

2022-06-23

10.1016/j.cell.2022.04.029

CELL   Impact Factor & Quartile

0092-8674

1097-4172

Breakthrough infections by SARS-CoV-2 variants become the global challenge for pandemic control. Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. Here, we developed a chimeric RBD-dimer vaccine approach to adapt SARS-CoV-2 variants. A prototype-Beta chimeric RBD-dimer was first designed to adapt the resistant Beta variant. Compared with its homotypic forms, the chimeric vaccine elicited broader sera neutralization of variants and conferred better protection in mice. The protection of the chimeric vaccine was further verified in macaques. This approach was generalized to develop Delta-Omicron chimeric RBD-dimer to adapt the currently prevalent variants. Again, the chimeric vaccine elicited broader sera neutralization of SARS-CoV-2 variants and conferred better protection against challenge by either Delta or Omicron SARS-CoV-2 in mice. The chimeric approach is applicable for rapid updating of immunogens, and our data supported the use of variant-adapted multivalent vaccine against circulating and emerging variants.

COVID19 vaccine Delta variant immunogen structure Omicron variant RBD receptor-binding domain SARS-CoV-2 vaccine protection variant of concern VOC

SCI

English

NI Journal Papers

Corresponding

China Postdoctoral Science Foundation[2020T130031ZX];National Natural Science Foundation of China[32100129];National Natural Science Foundation of China[81991494];National Natural Science Foundation of China[82041048];National Natural Science Foundation of China[82122031];Bill and Melinda Gates Foundation[INV-027420];Chinese Academy of Sciences[YSBR-010];

WOS:000823647900001

MOLECULAR BIOLOGY & GENETICS

2-s2.0-85130405575

Scopus

1.Research Network of Immunity and Health (RNIH),Beijing Institutes of Life Science,Chinese Academy of Sciences,Beijing,100101,China
2.CAS Key Laboratory of Pathogen Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing,100101,China
3.University of Chinese Academy of Sciences,Beijing,100049,China
4.Cryo-EM Center,Southern University of Science and Technology,Shenzhen,518055,China
5.National Kunming High-level Biosafety Primate Research Center,Institute of Medical Biology,Chinese Academy of Medical Sciences and Peking Union Medical College,Kunming,650031,China
6.NHC Key Laboratory of Biosafety,National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China
7.Zhejiang University School of Medicine,Hangzhou,310058,China
8.School of Public Health,Cheeloo College of Medicine,Shandong University,Jinan,250012,China
9.Department of Basic Medical Sciences,School of Medicine,Tsinghua University,Beijing,100084,China
10.Faculty of Health Sciences,University of Macau,Macau,SAR,999078,Macao
11.State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources,Guangxi University,Nanning,530004,China
12.Savaid Medical School,University of Chinese Academy of Sciences,Beijing,101408,China
13.School of Life Sciences,Yunnan University,Kunming,650091,China
14.Anhui Zhifei Longcom Biopharmaceutical Co. Ltd,Hefei,230088,China
15.Chongqing Medleader Bio-Pharm,Chongqing,401338,China
16.State Key Laboratory of Medical Molecular Biology,Department of Molecular Biology and Biochemistry,Institute of Basic Medical Sciences,Medical Primate Research Center,Neuroscience Center,Chinese Academy of Medical Sciences,School of Basic Medicine,Peking Union Medical College,Beijing,100005,China

Xu，Kun,Gao，Ping,Liu，Sheng,et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2[J]. CELL,2022,185(13):2265-2278.e14.

Xu，Kun.,Gao，Ping.,Liu，Sheng.,Lu，Shuaiyao.,Lei，Wenwen.,...&Gao，George F..(2022).Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.CELL,185(13),2265-2278.e14.

Xu，Kun,et al."Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2".CELL 185.13(2022):2265-2278.e14.